

Haseltine Law Office

1629 K Street, NW Suite 300
Washington, DC 20006
703 627 2652; fax 703 372 5173
Email: william@wbhlaw.net

611 E Glenoaks Blvd
Glendale, CA 91207
818 291 0661; fax 703 372 5173
URL: www.wbhlaw.net

June 20, 2014

OTC Markets
304 Hudson Street, 3d Floor
New York, NY 10013

Re: PTA Holdings, Inc.

Dear Sir or Madam:

We have been asked by PTA Holdings, Inc. (the "Issuer") to provide OTC Markets a letter with respect to the information publicly disclosed by the Issuer and published in the OTC Markets News Service. Prescribed periodic disclosure statements have been submitted to OTC Markets. I understand that this letter will be posted by the Issuer, and will be published, accompanying the Issuer's disclosure, in the OTC Markets News Service. OTC Markets is entitled to rely on such letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

I am a U.S. resident and have been retained by the Issuer for the purpose of rendering this letter and related matters. I am serving as a regular disclosure counsel for the Issuer, and have been retained also for the purpose of reviewing the current information supplied by the issuer. I have examined such corporate records and other documents and such questions of law, as I have considered necessary or appropriate for purposes of rendering this letter.

I am licensed to practice law in California and the District of Columbia, and practiced ten years for the U.S. Securities and Exchange Commission ("SEC"). I am allowed to practice before the SEC, and have never been prohibited from practicing before them. This letter applies to the United States of America and all jurisdictions therein. As to matters of fact, I have relied on information obtained from public officials, officers of the Issuer and other sources, and all such sources are believed to be reliable.

On June 9, 2014, I reviewed the disclosure entitled "Officer/Director Disclosure - Year End Disclosure Statement" filed by the Company February 12, 2014, for the fiscal year ending December 31, 2013. I also reviewed disclosure for the same fiscal year entitled "Annual Report - Year-end Financial Statement" filed February, 12, 2014 and "Annual Report - Income Statement Corrected 2013 Revenue," filed on March 1, 2014. Since the end of fiscal year 2013, one quarterly report has become due and has been filed. I have reviewed the "Quarterly Report - Financial Statements" for the quarter ending March 31, 2014, filed May 15, 2014, and the "Quarterly Report - Quarterly Information and Disclosure Statement," filed June 6, 2014, for the same quarter. On June 20, 2014, I reviewed the amendment to the Quarterly Report for the period ended March 31, 2014, published on June 12, 2014, and the amended financial statements for fiscal year ended December 31, 2013 published in an amended Annual Report on June 19, 2014.

These documents contain all the information required to be filed at year end of the Company for 2013, as set forth in §2 of the Guidelines for Providing Adequate Current Information, §§1-9 of the Issuer's Continuing Disclosure Obligations for quarterly reports. These documents were filed in connection with the Issuer's ongoing reporting obligations with the OTC Markets News Service. This letter is submitted in connection with the performance of these obligations.

The Information referred to herein (i) constitutes "adequate current public information" concerning the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11, (iii) complies as to substance with the OTC Markets Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com, and (iv) is posted in the OTC Markets News Service.

The person responsible for preparing the financial statements contained in the disclosure by the issuer is L. Lewensohn, who is qualified to prepare such financial statements by virtue of professional experience and education. The financial statements have not been audited. The Issuer's transfer agent is Manhattan Transfer, Inc. (the "Agent"). The Agent is registered with the SEC. Today, the Agent confirmed telephonically the number of issued and outstanding shares of the issuer - 1,630,649,910.

I also have (i) met with management and a majority of the directors of the Issuer, (ii) reviewed the Information, as amended, published by the Issuer on the OTC Markets News Service and (iii) discussed the Information with management and a majority of the directors of the Issuer.

To the best of my knowledge, after inquiry of management and the directors of the Issuer, neither the issuer of the Securities, any 5% holder, or any counsel is currently under investigation by any federal or state regulatory authority for any violation of Federal or state securities laws.

OTC Markets

June 20, 2014

Page 3

No person other than OTC Markets is entitled to rely on this letter; however, OTC Markets has permission to publish the letter in the OTC Markets News Service for viewing by the public and regulators. As of this date, there have been no promotional activities regarding the Securities covered hereby.

Sincerely,

A handwritten signature in black ink, appearing to read "W B Haseltine", written in a cursive style.

William B. Haseltine,
Attorney at Law